DRAGARWQ

Dr Agarwals Eye Hospital Limited

Dr Agarwals Eye Hospital Limited (DRAGARWQ) financial statements and selected valuation metrics through 30 June 2026.

Healthcare›Healthcare›Healthcare Services›Hospital

dragarwal.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹5077.00
Market cap
2,452 Cr
Stock P/E
32.2
P/B
7.08
Dividend yield
0.1%
ROE (FY26)
20.2%
ROCE (FY26)
24.6%
Operating margin (FY26)
21.2%
Debt / equity (FY26)
0.24
OCF / EBITDA (FY26)
99.9%
OCF / EBITDA (3Y)
92.8%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Chain of eye hospitals and clinics, mostly in Tamil Nadu, offering cataract, glaucoma, laser vision correction, cornea, retina and squint treatment; the company calls itself a leading eye hospital chain (its own description).

Company snapshot

19thBy market cap

Ranked among 24 companies in Hospital.

What we see

Positives
  • ✓93% of operating profit came in as cash over the last three years — profits are backed by real cash.
2 more signals from the filings.Sign in free to see them all

Statement tables · Standalone

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Standalone only

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales83 Cr76 Cr81 Cr100 Cr102 Cr95 Cr100 Cr117 Cr118 Cr116 Cr120 Cr143 Cr
Operating expenses (approx.)61 Cr55 Cr56 Cr69 Cr72 Cr69 Cr68 Cr80 Cr78 Cr82 Cr86 Cr100 Cr
EBITDA22 Cr20 Cr24 Cr31 Cr30 Cr26 Cr32 Cr37 Cr40 Cr34 Cr34 Cr43 Cr
OPM %26.9%27.1%30.3%31.4%29.2%26.9%31.6%31.8%34.0%29.6%28.1%30.3%
Other income2 Cr0.95 Cr2 Cr0.40 Cr2 Cr2 Cr0.10 Cr0.80 Cr0.68 Cr3 Cr2 Cr2 Cr
Interest2 Cr2 Cr2 Cr3 Cr4 Cr4 Cr3 Cr4 Cr4 Cr2 Cr2 Cr3 Cr
Depreciation6 Cr7 Cr8 Cr10 Cr9 Cr10 Cr10 Cr11 Cr11 Cr12 Cr12 Cr11 Cr
Profit before tax17 Cr13 Cr17 Cr19 Cr19 Cr14 Cr19 Cr23 Cr26 Cr23 Cr21 Cr31 Cr
Tax %24.4%25.8%26.2%25.4%26.0%26.0%14.0%25.6%24.9%26.3%23.6%24.5%
Net profit13 Cr9 Cr13 Cr14 Cr14 Cr10 Cr16 Cr17 Cr19 Cr17 Cr16 Cr23 Cr
EPS (₹)₹26.79₹20.09₹27.21₹30.02₹30.11₹22.13₹34.02₹36.72₹41.04₹35.76₹33.60₹48.38

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales149 Cr153 Cr170 Cr176 Cr140 Cr201 Cr268 Cr319 Cr397 Cr471 CrSign in free for the trailing twelve months
Operating expenses (approx.)127 Cr130 Cr141 Cr130 Cr109 Cr144 Cr193 Cr228 Cr279 Cr326 CrSign in free for the trailing twelve months
EBITDA21 Cr23 Cr29 Cr46 Cr30 Cr58 Cr75 Cr91 Cr119 Cr145 CrSign in free for the trailing twelve months
OPM %14.4%15.3%17.0%26.3%21.7%28.7%27.9%28.5%29.8%30.9%Sign in free for the trailing twelve months
Other income2 Cr2 Cr2 Cr3 Cr0.81 Cr1 Cr2 Cr5 Cr5 Cr6 CrSign in free for the trailing twelve months
Interest3 Cr3 Cr3 Cr8 Cr6 Cr6 Cr7 Cr7 Cr13 Cr12 CrSign in free for the trailing twelve months
Depreciation9 Cr10 Cr11 Cr21 Cr19 Cr20 Cr20 Cr27 Cr39 Cr46 CrSign in free for the trailing twelve months
Profit before tax11 Cr13 Cr17 Cr20 Cr6 Cr32 Cr49 Cr62 Cr71 Cr94 CrSign in free for the trailing twelve months
Tax %33.1%49.3%31.6%31.4%125.1%25.4%25.3%25.5%22.7%25.1%Sign in free for the trailing twelve months
Net profit7 Cr7 Cr12 Cr14 Cr-1 Cr24 Cr37 Cr46 Cr55 Cr70 CrSign in free for the trailing twelve months
EPS (₹)₹15.61₹14.42₹25.35₹29.11₹-3.06₹51.29₹78.55₹98.64₹116.28₹147.02Sign in free for the trailing twelve months
Dividend payout %—————0.1%3.8%5.6%4.3%4.4%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital5 Cr5 Cr5 Cr5 Cr5 Cr5 Cr5 Cr5 Cr5 Cr5 Cr
Reserves25 Cr30 Cr41 Cr51 Cr50 Cr73 Cr109 Cr152 Cr205 Cr341 Cr
Borrowings16 Cr10 Cr18 Cr13 Cr17 Cr32 Cr44 Cr51 Cr96 Cr82 Cr
Other liabilities27 Cr36 Cr36 Cr71 Cr84 Cr204 Cr233 Cr287 Cr307 Cr338 Cr
Total liabilities72 Cr81 Cr100 Cr141 Cr155 Cr314 Cr390 Cr496 Cr613 Cr766 Cr
Fixed assets (net)33 Cr32 Cr52 Cr55 Cr57 Cr59 Cr85 Cr121 Cr160 Cr375 Cr
CWIP1 Cr3 Cr0.25 Cr0.02 Cr0 Cr26 Cr62 Cr97 Cr128 Cr197 Cr
Investments——0 Cr0 Cr0 Cr0 Cr0 Cr0 Cr13 Cr89 Cr
Loans & advances——5 Cr2 Cr1 Cr0 Cr0 Cr0 Cr0 Cr0 Cr
Inventories6 Cr7 Cr6 Cr8 Cr5 Cr6 Cr6 Cr10 Cr13 Cr14 Cr
Trade receivables7 Cr7 Cr9 Cr7 Cr9 Cr9 Cr10 Cr13 Cr14 Cr19 Cr
Cash & bank2 Cr2 Cr4 Cr6 Cr22 Cr28 Cr27 Cr33 Cr11 Cr7 Cr
Other assets23 Cr29 Cr23 Cr62 Cr61 Cr186 Cr199 Cr222 Cr274 Cr66 Cr
Total assets72 Cr81 Cr100 Cr141 Cr155 Cr314 Cr390 Cr496 Cr613 Cr766 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity20 Cr19 Cr25 Cr39 Cr34 Cr57 Cr70 Cr90 Cr94 Cr145 Cr
Cash from investing-8 Cr-11 Cr-25 Cr-17 Cr-11 Cr-46 Cr-71 Cr-70 Cr-133 Cr-174 Cr
Cash from financing-12 Cr-8 Cr2 Cr-20 Cr-8 Cr-4 Cr0.26 Cr-14 Cr17 Cr25 Cr
Net cash flow0.42 Cr-0.46 Cr2 Cr2 Cr15 Cr7 Cr-0.73 Cr6 Cr-22 Cr-4 Cr
Free cash flow (OCF − Capex)12 Cr7 Cr0.27 Cr21 Cr23 Cr10 Cr-1 Cr18 Cr-7 Cr47 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %31.4%35.1%31.4%39.9%16.9%35.0%35.8%33.3%27.5%24.6%
ROE %25.0%19.3%26.1%24.4%-2.6%30.8%32.6%29.5%26.1%20.2%
Debtor days16171814231614151314
Inventory days15171281714108111211
Days payable344230228464636362821
Cash conversion cycle-3-7-1553-10-20-14-10-35
OCF / EBITDA %94.1%79.3%86.6%83.5%111.5%98.3%93.2%98.6%79.7%99.9%
OCF / EBITDA % (3 years)——86.4%83.4%92.4%96.2%98.4%96.7%89.3%92.8%
Debt / equity0.550.290.400.240.310.410.390.330.460.24
Current ratio0.730.620.840.750.910.960.840.740.641.23
Net debt / EBITDA0.650.360.480.15-0.160.070.220.200.720.52